Skip to content
Unjha Formulations logo

Unjha Formulations

531762 BSE
₹27.88

Close ·

P/E
25.81
View as Markdown
MCP
Close 4 Nov 2026 ₹27.88 +4.89 +21.3% 1Y
Start ₹22.99

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
27.80%
Debt to Equity
0.00
EPS (TTM)
₹1.08
Book Value
₹8.58
Market Cap
—
P/E (TTM)
25.81
P/B
3.25
ROE
20.10%
Dividend Yield
0.00%
EBITDA
₹1.10 Cr
52W High
₹36.38
52W Low
₹17.52

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

62 Good

Data confidence 98/100

Category scores

Quality
76
Strong
Returns, margins, earnings quality 22% weight
Valuation
49
Average
Cheap vs sector & own history 24% weight
Growth
56
Good
Sales & profit trajectory 9% weight
Financial Health
75
Strong
Solvency, leverage, coverage 9% weight
Momentum
88
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

2
  • The company has delivered a poor sales growth of 9.37% over past five years.
  • Promoter holding is low: 36.9%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallNeutral676
OscillatorsBearish270
Moving AveragesStrong Bullish406

Key readings

RSI (14)
44.37
Neutral
MACD (12,26,9)
−1.08
Bearish
SMA (50)
30.23
Bearish
SMA (200)
23.92
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+4.17%
5Y+9.37%
3Y+5.84%
1Y+12.48%
TTM+12.93%

Net profit

Net profit growth by window
10Y+10.41%
5Y+47.58%
3Y+35.72%
1Y+70.73%
TTM+433.33%

Operating cash flow

Operating cash flow growth by window
10Y+11.70%
5YTurned positive
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+2.62 pp
5Y+4.78 pp
3Y+2.74 pp
1Y+2.34 pp
TTM+3.14 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹12.23 Cr
Mar 2018₹11.30 Cr
Mar 2019₹11.28 Cr
Mar 2020₹10.59 Cr
Mar 2021₹9.96 Cr
Mar 2022₹14.16 Cr
Mar 2023₹13.15 Cr
Mar 2024₹18.50 Cr
Mar 2025₹13.86 Cr
Mar 2026₹15.59 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.30 Cr
Mar 2018₹0.26 Cr
Mar 2019₹0.30 Cr
Mar 2020₹0.31 Cr
Mar 2021₹0.10 Cr
Mar 2022₹0.25 Cr
Mar 2023₹0.28 Cr
Mar 2024₹0.28 Cr
Mar 2025₹0.41 Cr
Mar 2026₹0.70 Cr

Quarterly Results

₹ Cr
531762 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
3.76
4.76
5.55
4.43
3.95
3.78
3.76
2.44
3.63
4.29
4.44
3.33
3.31
Expenses
3.54
4.87
5.14
4.37
3.23
3.89
3.52
2.7
3.21
3.5
4.16
3.78
3.12
Operating Profit
0.22
−0.11
0.41
0.06
0.72
−0.11
0.24
−0.26
0.42
0.79
0.28
−0.45
0.19
OPM %
5.85%
−2.31%
7.39%
1.35%
18.23%
−2.91%
6.38%
−10.66%
11.57%
18.41%
6.31%
−13.51%
5.74%
Other Income
−0.01
0.01
0
0.01
0
0.02
0.01
0
0
0.06
0
0
0
Interest
0.02
0
0
0.05
0
0
0
0
0
0
0
0
0
Depreciation
0
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.03
0.04
0.04
0.04
PBT
0.19
−0.12
0.39
0
0.7
−0.11
0.23
−0.29
0.39
0.82
0.24
−0.49
0.15
Tax %
0%
0%
0%
—
0%
0%
0%
41.38%
0%
0%
0%
51.02%
0%
Net Profit
0.18
−0.12
0.39
−0.18
0.7
−0.11
0.22
−0.41
0.39
0.82
0.24
−0.74
0.16
EPS (₹)
0.4
−0.27
0.87
−0.4
1.56
−0.25
0.49
−0.92
0.87
1.83
0.54
−1.65
0.36

Profit & Loss

₹ Cr
531762 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
8.84
10.36
12.23
11.3
11.28
10.59
9.96
14.16
13.15
18.5
13.86
15.59
15.37
Expenses
8.65
10
11.86
10.96
10.98
10.34
9.83
13.84
12.71
17.93
13.34
14.64
14.56
Operating Profit
0.19
0.36
0.37
0.34
0.3
0.25
0.13
0.32
0.44
0.57
0.52
0.95
0.81
OPM %
2.15%
3.47%
3.03%
3.01%
2.66%
2.36%
1.31%
2.26%
3.35%
3.08%
3.75%
6.09%
5.27%
Other Income
0.09
0.08
0.11
0.04
0.1
0.26
0.22
0.19
0.03
0.01
0.11
0.16
0.06
Interest
0.01
0.1
0.1
0.02
0.01
0.12
0.17
0.13
0.06
0.05
0.01
0.01
0
Depreciation
0.09
0.08
0.09
0.1
0.09
0.08
0.08
0.08
0.08
0.08
0.1
0.14
0.15
PBT
0.18
0.26
0.29
0.26
0.3
0.31
0.1
0.3
0.33
0.45
0.52
0.96
0.72
Tax %
0%
0%
0%
0%
0%
0%
0%
16.67%
15.15%
40%
23.08%
26.04%
—
Net Profit
0.17
0.26
0.3
0.26
0.3
0.31
0.1
0.25
0.28
0.28
0.41
0.7
0.48
EPS (₹)
0.38
0.58
0.67
0.58
0.67
0.69
0.22
0.56
0.62
0.62
0.92
1.56
1.08
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
531762 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
4.48
Reserves
−4.09
−3.83
−3.54
−3.27
−2.97
−2.67
−2.56
−2.31
−2.03
−1.75
−1.34
−0.64
Borrowings
0.4
0
0.05
0
0
0
0
0
0
0
0
0
Other Liabilities
2.51
2.28
2.79
2.75
2.15
1.9
1.61
1.28
0.96
2.2
1.42
1.67
Total Liabilities
3.3
2.93
3.78
3.96
3.66
3.71
3.53
3.45
3.41
4.93
4.56
5.51
Fixed Assets
1.09
1.03
1.22
1.16
1.12
1.14
1.12
1.07
1.1
1.12
1.2
1.3
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
2.21
1.9
2.56
2.8
2.54
2.57
2.41
2.38
2.31
3.81
3.36
4.21
Total Assets
3.3
2.93
3.78
3.96
3.66
3.71
3.53
3.45
3.41
4.93
4.56
5.51

Cash Flow

₹ Cr
531762 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−0.7
0.41
0.39
0.14
−0.12
0.39
−0.7
0.28
−0.26
1.03
−0.04
1.24
Investing
−0.09
−0.02
−0.28
0.06
0.04
−0.1
−0.06
−0.02
−0.1
−0.11
−0.18
−0.23
Financing
0.4
−0.4
0.05
−0.05
0.23
0
0
0
−0.06
−0.05
−0.01
−0.01
Net Cash Flow
−0.38
−0.01
0.15
0.15
0.16
0.29
−0.77
0.25
−0.42
0.86
−0.23
1
Free Cash Flow
−0.78
0.39
0.11
0.2
−0.08
0.29
−0.76
0.26
−0.36
0.92
−0.22
1.01
CFO/OP
−368
114
105
41
−37
204
−408
88
−48
189
19
156

Ratios

531762 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28.08
28.54
19.4
25.19
43.36
39.64
35.91
18.04
29.14
31.76
39.77
31.61
Inventory Days
35.62
22.76
40.83
39.4
22.92
21.37
55.6
34.08
38.92
29.56
32.92
19.1
Days Payable
122
94.35
98.2
106
87.5
82.79
77.35
39.81
32.1
47.85
37.39
39.71
Cash Conversion Cycle
−58.78
−43.06
−37.97
−41.63
−21.22
−21.79
14.16
12.31
35.97
13.47
35.29
10.99
Working Capital Days
−46.66
−28.19
−24.17
−21.96
−8.41
−9.31
22.72
17.27
37.19
14.6
34.24
21.31
ROCE %
37.62%
50%
47.56%
25.45%
22.79%
25.9%
14.48%
21.03%
16.88%
19.31%
18.06%
27.79%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Unjha Formulations insights

60 extracted metrics across FY09–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 56.72%
  • Promoters 36.92%
  • Others 6.35%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Unjha Formulations

What does Unjha Formulations Ltd do?
Incorporated in 1991, Unjha Formulations Ltd is a manufacturer and exporter of psyllium husk-based products.
Where is Unjha Formulations Ltd (UNJHAFOR) listed?
Unjha Formulations Ltd trades under code 531762 on the BSE.
Which sector does Unjha Formulations Ltd belong to?
Unjha Formulations Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Unjha Formulations Ltd?
Unjha Formulations Ltd trades at a PE ratio of 25.81 as of 4 Nov 2026, on earnings per share of ₹1.08, against a book value of ₹8.58 per share.
What is the 52-week high and low of Unjha Formulations Ltd?
Over the last 52 weeks Unjha Formulations Ltd has traded between ₹17.52 and ₹36.38 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Unjha Formulations Ltd?
Unjha Formulations Ltd reported a return on equity of 20.10%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1991, Unjha Formulations Ltd is a manufacturer and exporter of psyllium husk-based products.

Website unjhaformulations.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531762.md for Unjha Formulations Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month